Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Ezetimibe

Ezetimibe

Introduction

Cardiovascular diseases remain one of the leading causes of mortality globally, and elevated cholesterol levels are a major risk factor. Statins are commonly prescribed lipid-lowering agents; however, not all patients can tolerate statins or achieve target lipid levels with statins alone. This necessitates the use of additional or alternative therapies. One such drug is Ezetimibe, a cholesterol absorption inhibitor that provides a unique mechanism of action in the management of hypercholesterolemia. Approved by the FDA in 2002, Ezetimibe is often used alone or in combination with statins to improve lipid profiles and reduce cardiovascular risks.

Mechanism of Action

Ezetimibe works by selectively inhibiting the Niemann-Pick C1-Like 1 (NPC1L1) protein found in the small intestine. This protein is essential for the intestinal uptake of cholesterol. By inhibiting NPC1L1, Ezetimibe reduces the absorption of dietary and biliary cholesterol at the brush border of the small intestine. This leads to a decrease in the delivery of cholesterol to the liver, resulting in increased clearance of cholesterol from the blood and a reduction in total cholesterol, low-density lipoprotein cholesterol (LDL-C), and other atherogenic lipids.

Pharmacokinetics

  • Absorption: Ezetimibe is rapidly absorbed and extensively metabolized in the intestinal wall and liver to its active metabolite, ezetimibe-glucuronide.

  • Distribution: It has a plasma protein binding rate of >90%.

  • Metabolism: Primarily metabolized via glucuronidation.

  • Excretion: Elimination is primarily through the feces (78%) and urine (11%).

  • Half-life: Approximately 22 hours, supporting once-daily dosing.

Indications and Uses

Ezetimibe is indicated for:

  1. Primary Hyperlipidemia: Used as monotherapy or in combination with statins.

  2. Homozygous Familial Hypercholesterolemia (HoFH): Used with statins.

  3. Homozygous Sitosterolemia (Phytosterolemia): Reduces elevated sitosterol and campesterol levels.

  4. Prevention of Cardiovascular Events: Especially when combined with statins in high-risk patients.

Dosage and Administration

The recommended dose of Ezetimibe is 10 mg once daily, with or without food. It can be used alone or with a statin or fenofibrate. No dosage adjustment is required in elderly patients or those with mild-to-moderate hepatic or renal impairment.

Combination Therapy

Ezetimibe is frequently prescribed in combination with statins such as simvastatin, atorvastatin, or rosuvastatin. The combination enhances LDL-C reduction by attacking cholesterol from two angles—reducing synthesis in the liver (statins) and absorption in the intestine (Ezetimibe). Fixed-dose combinations like Ezetimibe-Simvastatin (Vytorin) are widely used.

Clinical Efficacy

Numerous clinical trials support the efficacy of Ezetimibe:

  • IMPROVE-IT Trial: Demonstrated that adding Ezetimibe to simvastatin significantly reduced cardiovascular events in patients with acute coronary syndrome compared to simvastatin alone.

  • SHARP Trial: Ezetimibe combined with simvastatin reduced major atherosclerotic events in patients with chronic kidney disease.

Ezetimibe can reduce LDL-C by an additional 18–25% when added to a statin, making it a valuable adjunct therapy.

Side Effects and Safety Profile

Ezetimibe is generally well tolerated. Common side effects include:

  • Headache

  • Diarrhea

  • Myalgia

  • Fatigue

  • Upper respiratory tract infections

Rare but serious adverse effects:

  • Elevated liver enzymes (when used with statins)

  • Rhabdomyolysis

  • Hypersensitivity reactions including rash and angioedema

Monitoring of liver enzymes is advised when Ezetimibe is used in combination with statins.

Contraindications and Precautions

  • Contraindications:

    • Hypersensitivity to Ezetimibe

    • Active liver disease (especially when used with a statin)

    • Pregnancy and breastfeeding (when used with statins)

  • Precautions:

    • Use with caution in patients with severe hepatic impairment

    • Monitor lipid levels regularly to assess efficacy

Drug Interactions

  • Statins: Increased risk of liver enzyme elevations.

  • Cyclosporine: Can increase Ezetimibe levels; monitor levels closely.

  • Fibrates: Particularly gemfibrozil, can increase the risk of gallstones.

  • Cholestyramine: Reduces Ezetimibe’s bioavailability; administer at least 2 hours before or 4 hours after cholestyramine.

Use in Special Populations

  • Pregnancy and Lactation: Ezetimibe should only be used if clearly needed. Use in combination with statins is contraindicated in pregnancy.

  • Pediatrics: Safety and efficacy have been established in children aged 10 years and older.

  • Geriatrics: No overall difference in safety compared to younger adults.

Patient Counseling Points

  • Take Ezetimibe once daily, with or without food.

  • If prescribed with a statin or bile acid sequestrant, follow specific timing instructions.

  • Inform healthcare providers about all medications being taken.

  • Report any muscle pain, tenderness, or weakness.

  • Continue diet and exercise program as recommended.

Future Perspectives and Research

As the role of LDL-C in cardiovascular disease continues to be elucidated, Ezetimibe remains an important agent for combination therapy. Ongoing research is exploring its use with PCSK9 inhibitors and in broader primary prevention populations. Its non-statin mechanism of action also makes it an attractive option for statin-intolerant patients.

Conclusion

Ezetimibe offers a valuable alternative or adjunct to statins in the management of hypercholesterolemia. With a unique mechanism of action, favorable safety profile, and proven clinical efficacy, it has secured a critical place in lipid-lowering therapy. Whether used alone or in combination, Ezetimibe helps bridge the gap in achieving target lipid levels, thereby reducing the risk of cardiovascular events in various patient populations. As personalized medicine and combination therapies continue to evolve, Ezetimibe will likely remain a key component in the pharmacological arsenal against dyslipidemia.